51
|
Chou SHY, Lan J, Esposito E, Ning M, Balaj L, Ji X, Lo EH, Hayakawa K. Extracellular Mitochondria in Cerebrospinal Fluid and Neurological Recovery After Subarachnoid Hemorrhage. Stroke 2017; 48:2231-2237. [PMID: 28663512 DOI: 10.1161/strokeaha.117.017758] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 05/22/2017] [Accepted: 05/25/2017] [Indexed: 12/22/2022]
Abstract
BACKGROUND AND PURPOSE Recent studies suggest that extracellular mitochondria may be involved in the pathophysiology of stroke. In this study, we assessed the functional relevance of endogenous extracellular mitochondria in cerebrospinal fluid (CSF) in rats and humans after subarachnoid hemorrhage (SAH). METHODS A standard rat model of SAH was used, where an intraluminal suture was used to perforate a cerebral artery, thus leading to blood extravasation into subarachnoid space. At 24 and 72 hours after SAH, neurological outcomes were measured, and the standard JC1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanineiodide) assay was used to quantify mitochondrial membrane potentials in the CSF. To further support the rat model experiments, CSF samples were obtained from 41 patients with SAH and 27 control subjects. Mitochondrial membrane potentials were measured with the JC1 assay, and correlations with clinical outcomes were assessed at 3 months. RESULTS In the standard rat model of SAH, extracellular mitochondria was detected in CSF at 24 and 72 hours after injury. JC1 assays demonstrated that mitochondrial membrane potentials in CSF were decreased after SAH compared with sham-operated controls. In human CSF samples, extracellular mitochondria were also detected, and JC1 levels were also reduced after SAH. Furthermore, higher mitochondrial membrane potentials in the CSF were correlated with good clinical recovery at 3 months after SAH onset. CONCLUSIONS This proof-of-concept study suggests that extracellular mitochondria may provide a biomarker-like glimpse into brain integrity and recovery after injury.
Collapse
Affiliation(s)
- Sherry H-Y Chou
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.)
| | - Jing Lan
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.)
| | - Elga Esposito
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.)
| | - MingMing Ning
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.)
| | - Leonora Balaj
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.)
| | - Xunming Ji
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.)
| | - Eng H Lo
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.)
| | - Kazuhide Hayakawa
- From the Neuroprotection Research Laboratories, Departments of Radiology and Neurology (S.H.-Y.C., J.L., E.E., M.N., E.H.L., K.H.) and Clinical Proteomics Research Center, Department of Neurology (M.N., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Departments of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh, PA (S.H.-Y.C.); Department of Neurology, Brigham and Women's Hospital, Boston, MA (S.H.-Y.C.); Cerebrovascular Research Center, Xuanwu Hospital, Capital Medical University, Beijing, China (J.L., X.J.); and Department of Neurology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston (L.B.).
| |
Collapse
|
52
|
Zou J, Chen Z, Wei X, Chen Z, Fu Y, Yang X, Chen D, Wang R, Jenner P, Lu JH, Li M, Zhang Z, Tang B, Jin K, Wang Q. Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units. Cell Death Dis 2017; 8:e2854. [PMID: 28569795 PMCID: PMC5520899 DOI: 10.1038/cddis.2017.240] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Revised: 04/18/2017] [Accepted: 04/26/2017] [Indexed: 02/06/2023]
Abstract
Cystatin C (CYS C, Cst3) is an endogenous cysteine protease inhibitor that plays neuroprotective roles in neurodegenerative diseases. We aimed to explore the association of CYS C with Parkinson’s disease (PD) models and investigate its involvement in the role of neurovascular units (NVUs) in PD neuro-pathogenesis. We used A53T α-synuclein (SNCA) transgenic mice and 6-hydroxydopamine-lesioned DAergic PC12 cells as experimental PD models to investigate the mechanisms behind this association. The injections of CYS C were administered to the right substantia nigra (SN) of A53T SNCA transgenic mice to measure the effects of CYS C in transgenic A53T SNCA mice. To explore the angiogenesis in vivo and in vitro, we used the chick embryo chorioallantoic membrane (CAM) assay and tube formation (TF) assay. We found that CYS C has a neuroprotective effect in this in vivo PD model. We observed increased VEGF, NURR1 and autophagy markers LC3B and decreased SNCA and apoptosis marker cleaved CASP3 in different brain regions of CYS C-treated A53T SNCA transgenic mice. In vitro, we observed that CYS C-induced VEGF, a secreted protein, attenuated 6-OHDA-lesioned DAergic PC12 cell degeneration by regulating p-PKC-α/p-ERK1/2-Nurr1 signaling and inducing autophagy. VEGF-mediated angiogenesis was markedly enhanced in the conditioned media of 6-OHDA-lesioned PC12 cells with CYS C-overexpression, whereas blockage of autophagy in CYS C-overexpressing PC12 cells significantly downregulated VEGF expression and the associated angiogenesis. Our data indicate that CYS C displays dual neuronal–vascular functions, promoting PC12 cell survival and angiogenesis via regulating the level of secreted VEGF in NVUs. Our study provides evidence that may aid in the development of an alternative approach for the treatment of PD through modulation of CYS C-mediated neuronal-vascular pathways.
Collapse
Affiliation(s)
- Jing Zou
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Zhaoyu Chen
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Xiaobo Wei
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Zhigang Chen
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Yongmei Fu
- Department of Emergency, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Xiaoyan Yang
- Department of Emergency, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Dan Chen
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Rui Wang
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| | - Peter Jenner
- Neurodegenerative Diseases Research Group, Faculty of Health Sciences and Medicine, King's College, London SE1 1UL, UK
| | - Jia-Hong Lu
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, China
| | - Min Li
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
| | - Zhuohua Zhang
- Department of Neurology, Xiangya School of Medicine and The State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan 410078, China
| | - Beisha Tang
- Department of Neurology, Xiangya School of Medicine and The State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan 410078, China
| | - Kunlin Jin
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
| | - Qing Wang
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China
| |
Collapse
|
54
|
Diaz-Aparicio I, Beccari S, Abiega O, Sierra A. Clearing the corpses: regulatory mechanisms, novel tools, and therapeutic potential of harnessing microglial phagocytosis in the diseased brain. Neural Regen Res 2016; 11:1533-1539. [PMID: 27904472 PMCID: PMC5116820 DOI: 10.4103/1673-5374.193220] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Apoptosis is a widespread phenomenon that occurs in the brain in both physiological and pathological conditions. Dead cells must be quickly removed to avoid the further toxic effects they exert in the parenchyma, a process executed by microglia, the brain professional phagocytes. Although phagocytosis is critical to maintain tissue homeostasis, it has long been either overlooked or indirectly assessed based on microglial morphology, expression of classical activation markers, or engulfment of artificial phagocytic targets in vitro. Nevertheless, these indirect methods present several limitations and, thus, direct observation and quantification of microglial phagocytosis is still necessary to fully grasp its relevance in the diseased brain. To overcome these caveats and obtain a comprehensive, quantitative picture of microglial phagocytosis we have developed a novel set of parameters. These parameters have allowed us to identify the different strategies utilized by microglia to cope with apoptotic challenges induced by excitotoxicity or inflammation. In contrast, we discovered that in mouse and human epilepsy microglia failed to find and engulf apoptotic cells, resulting in accumulation of debris and inflammation. Herein, we advocate that the efficiency of microglial phagocytosis should be routinely tested in neurodegenerative and neurological disorders, in order to determine the extent to which it contributes to apoptosis and inflammation found in these conditions. Finally, our findings point towards enhancing microglial phagocytosis as a novel therapeutic strategy to control tissue damage and inflammation, and accelerate recovery in brain diseases.
Collapse
Affiliation(s)
- Irune Diaz-Aparicio
- Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain; University of the Basque Country, Leioa, Spain
| | - Sol Beccari
- Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain; University of the Basque Country, Leioa, Spain
| | - Oihane Abiega
- Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain; University of the Basque Country, Leioa, Spain
| | - Amanda Sierra
- Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain; University of the Basque Country, Leioa, Spain; Ikerbasque Foundation, Bilbao, Spain
| |
Collapse
|